Skip to main content

Table 1 Initial dose of S-1

From: A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy

Creatinine clearancea Body surface area Dose of S-1 (indicated as tegafur dose)
60 mL/min or more Less than 1.25 m2 80 mg/day
1.25 m2 or more, less than 1.5 m2 100 mg/day
1.5 m2 or more 120 mg/day
Less than 60 mL/min Less than 1.25 m2 50 mg/day
1.25 m2 or more, less than 1.5 m2 80 mg/day
1.5 m2 or more 100 mg/day
  1. aCreatinine clearance will be estimated from the Cockcroft-Gault formula, although actual measurement values will be used if available